NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Drug Manufacturers - General · USD

Novartis AG (NVS) Stock Analysis

Novartis AG (NVS) is a Drug Manufacturers - General stock listed on NYSE and quoted in US Dollar.

NVS

$159.99

−$3.10 (−1.90%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NVS with… →

NVS Key Statistics

As of Sep 4, 2026
Trading
Open
$159.90
Previous Close
$163.09
Day's Range
159.63–160.93
52-Week Range
121.57–170.46
Volume
1.29M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.49
Valuation
Market Cap
$304.10B
P/E Ratio
24.61
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
16.31
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
3.41
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.36
EPS (ttm)Profit attributable to each share over the last twelve months.
6.50
Financials (FY)
Revenue (FY)
$56.67B+9.57%
Net Income (FY)
$13.98B+17.11%
Profit marginThe share of revenue left as profit after all costs and taxes.
22.50%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.90B
1-Year Return
+28.38%
Dividend and dates
Dividend
$4.74+2.91%
Ex-Dividend Date
March 11, 2026
Earnings Date
October 27, 2026
Avg Volume
1.91M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NVS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+19.58%
2025+46.95%
2024+0.02%
2023+16.14%
2022+8.06%
2021−3.65%
2020+3.34%
2019+27.13%
2018+5.95%
2017+19.46%
2016 (partial year)−11.47%

As of September 4, 2026.

NVS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$56.67B$13.98B24.7%
2024$51.72B$11.94B23.1%
2023$46.66B$14.85B31.8%
2022$43.46B$6.96B16.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$56.67B$42.98B$17.64B$13.98B24.7%
2024$51.72B$38.90B$14.54B$11.94B23.1%
2023$46.66B$34.19B$9.77B$14.85B31.8%
2022$43.46B$31.88B$7.95B$6.96B16.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NVS Dividend History

$3.99+6.8% vs 2024

Dividends per share, 2025 · 1 payments

YearDividends per sharePaymentsChange
2026*$4.771—
2025$3.991+6.8%
2024$3.741+7.8%
2023$3.471+3.3%
YearDividends per sharePaymentsChange
2026 (partial year)$4.771—
2025$3.991+6.8%
2024$3.741+7.8%
2023$3.471+3.3%
2022$3.361−0.6%
2021$3.381+11.0%
2020$3.041+18.5%
2019$2.571−3.8%
2018$2.671+8.4%
2017$2.461—

Most recent payment: $4.77 per share, ex-dividend March 11, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

NVS Valuation vs Drug Manufacturers - General Median

Median of 21 stocks
MetricNVSDrug Manufacturers - General medianvs median
P/E24.6124.690% below
P/S ratio5.363.1371% above
Profit margin22.50%8.09%14.4 pts above

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Novartis AG (NVS) at $304.10B. The company sits in the Healthcare sector, in the Drug Manufacturers - General industry. Headcount on file is 75,267.

NVS last closed at $159.99 on September 4, 2026. That is −$3.10 (−1.90%) against the previous close. Over the past 52 weeks the price has ranged from $121.57 to $170.46. The latest close sits 31.6% above that 52-week low.

Financial Health

In fiscal 2025, Novartis AG reported revenue of $56.67B. That is +9.57% against the prior fiscal year, when revenue was $51.72B. The same year closed with net income of $13.98B. That is +17.11% against the prior fiscal year. The reported profit margin is 22.5%. That is 14.4 percentage points above the Drug Manufacturers - General median of 8.09%. Earnings per share on a trailing basis come to 6.5.

Across the 4 fiscal years on file, revenue moves from $43.46B in 2022 to $56.67B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 24.61. That is 0.32% below the Drug Manufacturers - General median of 24.69. The forward P/E on file is 16.31. The PEG ratio, which sets the P/E against expected earnings growth, reads 3.41. Measured against sales, the shares trade at 5.36 times revenue. On price-to-sales that is 71.28% above the Drug Manufacturers - General median of 3.13. 21 Drug Manufacturers - General companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.49. Daily returns over the trailing 10 years annualize to a volatility of 19.55%. The trailing one-year price return is +28.38%. Across 10 years the annualized return works out at +12.48%.

Growth & Income

The trailing dividend yield is 2.91%. That is 0.2 percentage points above the Drug Manufacturers - General median yield of 2.7%. At the indicated rate that is $4.74 a share a year. The ex-dividend date on file is March 11, 2026. Dividends are recorded for 10 calendar years; 2026 shows 1 payments totalling $4.77 a share. The year before, 2025, totalled $3.99 a share.

2026 is still running; the price is +19.58% year to date. Across the complete calendar years on file, 2025 returned +46.95% and 2021 returned −3.65%. Of the 9 complete calendar years on file, 8 finished higher.

Peer Comparison

Novartis AG (NVS) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Novartis AG NVS $304.10B 24.6
Eli Lilly and Company LLY $1.02T 38.6
Johnson & Johnson JNJ $663.28B 32.0
AbbVie Inc. ABBV $453.19B 73.5

The Drug Manufacturers - General industry average P/E ratio is 24.7x. Novartis AG trades at a P/E of 24.6.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 AZN

AstraZeneca PLC

$252.33B

 AMGN

Amgen Inc.

$236.38B
View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$356.47B

 TMO

Thermo Fisher Scientific Inc.

$226.94B

 NVO

Novo Nordisk A/S

$206.02B

 ABT

Abbott Laboratories

$187.45B

 GILD

Gilead Sciences, Inc.

$187.23B
View all Healthcare stocks →

About Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Visit website →